Pharmacyclics (PCYC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: squetch who wrote (268)	3/4/1998 3:37:00 PM
From: Biomaven	Read Replies (2) of 717

squetch, You should have posted this one here too: Message 3598295 The ongoing photosensitivity from the existing QLTIF drug (Photofrin) is apparently a significant problem that PCYC's Lu-Tex doesn't have. A urologist I know casually told me that he participated in an early trial of QLT's drug for bladder cancer, and the patient had to stay indoors for weeks. My view is that both QLTIF and Miravant are preparing the way for PCYC's better drug, and the more success they have now the better for PCYC if and when its drug is approved. I tried to find what wavelength the Miravant drug(s) use, but have been unable to do so. Any ideas where to look? Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next